Skip to Main Content

Try STAT+ TODAY

immunotherapy

Most Read

pills

Pharmalot By Ed Silverman

European regulator suspends generic drugs after finding flawed studies

Health By Andrew Joseph

U.S. reports 180 cases of unexplained hepatitis in children, as researchers investigate potential causes

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Biotech By Jonathan Wosen

‘No real clear path’: Insurance coverage for cutting-edge diagnostics remains a major challenge for personalized medicine

Pharmalot By Ed Silverman

Pharmalittle: Cancer coalition aims to boost access to meds in poor countries; Moderna’s vaccine patent defense poses shield for others

emergency care doors

First Opinion By Michael L. Millenson and J. Matthew Austin

To improve safety, hospitals should make ‘radical transparency’ real — and accessible

First Opinion By Steven C. Schlozman

Hopelessness around youth mental health is creating a ‘nihilistic contagion’

Health By Olivia Goldhill

Vague ‘medical emergency’ exceptions in abortion laws leave pregnant people in danger, doctors say

All Coverage

Healthy human T cell

Politics By Casey Ross

Medicare proposes a boost in payments for CAR-T and other breakthrough drugs and devices

Breast Cancer Cell NCI National Cancer Institute

Health By Sharon Begley

Roche scores first U.S. approval of immunotherapy for breast cancer

advertisement

First Opinion By Neil Canavan

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds

Assasin within First Opinion illustration

First Opinion By Doreen Carvajal

Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope

Elderly Immunotherapy

First Opinion By Ankur Parikh

We need more answers about immunotherapy for the elderly

Immunotherapy scans

First Opinion By Raymond J. Tesi

Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay

Killer T cells surround a cancer cell

Adam's Take By Adam Feuerstein

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

Health By Associated Press

In a milestone year, gene therapy is finding a place in medicine

Colontown

Health By David Steen Martin

‘Colontown’ gives cancer patients an edge in finding new treatments

T-Cells and cancer

Lab Chat By Megan Thielking

Insight into exhausted immune cells could open new doors for cancer therapy

Rachel Lefebvre

Health By Bob Tedeschi

For cancer patients, newest treatments force the ultimate decision, with no room for error

Human T lymphocyte

Biotech By Damian Garde

Separating hope from hype in the latest cancer treatment ‘revolution’

ASH19 CAR-T and cancer cell

Biotech By Damian Garde

Novel cancer treatment from Kite Pharma notches positive results, but big questions remain

T-Cells and cancer

Biotech By Sharon Begley

Beware the hype: Top scientists cautious about fighting cancer with immunotherapy

Car-T challenges

Biotech By Meghana Keshavan

Hurdles abound in race to bring customized cancer treatments to masses

ASH19 CAR-T and cancer cell

Biotech By Meghana Keshavan

Experimental cancer therapy holds great promise — but at great cost

Mick Phillips

Health By Rob Waters

Facing bleak odds, cancer patients chase one last chance — in Cuba

Paul Mihocko

In the Lab By Sharon Begley

In cancer, it’s back to the future as old treatments make cutting-edge ones more effective

Stephen Estrada

Health By Rebecca Robbins

For cancer patients on experimental immunotherapy drugs, it’s been an emotional week

Hans Bishop

Biotech By Damian Garde

FDA lets cancer trial resume after three patient deaths

Dendreon Corporation

Biotech By Sharon Begley

In Juno patient deaths, echoes seen of earlier failed company

T-Cells and cancer

Biotech By Damian Garde

After a deadly clinical trial, will immune therapies for cancer be a bust?

FDA

Biotech By Damian Garde and Meghana Keshavan

Juno halts its immunotherapy trial for cancer after three patient deaths

Siddhartha Mukherjee

Business By Damian Garde

Pulitzer Prize-winning doctor wades into biotech with cancer startup

Sean Parker & Craig Venter

Business By Sharon Begley

Sean Parker’s put up big bucks for cancer. We’ve got questions